Skip to content

Depression: all studies

Page 586 of 1,036: studies 5,851 to 5,860 of 10,358, newest first. Back to the depression overview

Research

The effect of low-dose psilocybin on brain neurotransmission and rat behavior.

Progress in Neuro-Psychopharmacology and Biological Psychiatry April 2, 2025 Agnieszka Bysiek, Adam Wojtas, Izabela Szpręgiel et al. 10 citations

Psilocybin has various therapeutic effects in mental and psychological disorders, including depression and mood disorders, obsessive-compulsive disorders, substance addiction and anxiety. Pharmacodynamic properties of psilocybin depend on doses used and time after administration. The psilocybin dose range varies depending on whether it is used therapeutically or for recreational purposes in...

Psilocybin has a narrow therapeutic window as an antidepressant treatment.

Progress in Neuro-Psychopharmacology and Biological Psychiatry April 2, 2025 Lenka Seillier, Barbora Čechová, Alexandre Seillier et al. 3 citations

Psilocybin, a naturally occurring psychedelic compound in magic mushrooms, shows promise as a novel intervention with a single administration inducing rapid and long-lasting antidepressant effects. However, there are limited studies on the optimal dosing required for the beneficial effects of psilocybin given its side effects. To address this gap, we investigated in Wistar rats whether a single...

DOI: 10.1016/j.pnpbp.2025.111368 (opens in new tab) Full text (opens in new tab) Antidepressant-like behavior Head-twitch response Locomotor activity Rectal temperature +6

Feasibility, acceptability, and fidelity of remote-delivered abbreviated mindfulness-based cognitive therapy interventions for patients with migraine and depressive symptoms.

Headache: The Journal of Head and Face Pain April 1, 2025 Elizabeth K. Seng, Jacob D Hill, Annie Kate Reeder et al.

This study was an open-label single-arm clinical trial evaluating the fidelity, feasibility, acceptability, and clinical signal of abbreviated mindfulness-based cognitive therapy (MBCT-brief) delivered either via telephone (MBCT-T) or by video conferencing (MBCT-V) for people with migraine and comorbid depressive symptoms. Migraine is commonly comorbid with elevated depressive symptoms. MBCT...

Disturbing dreams, nightmares, and psychological distress are predictors of poor sleep quality.

University Library Heidelberg April 1, 2025 Ian C. Dunican, Hailey Meaklim, Mitchell Turner et al.

Objective: Up to 40% of adults report poor sleep quality, yet research investigating the role of nightmares on sleep quality is limited. This study aimed to characterise the prevalence of disturbing dreams and nightmares and their relationship to poor sleep quality. Method: 439 adults (310 females, Mage=44.9 years) completed an online survey investigating sleep, dreams, nightmares, and mental...

Salivary Oxytocin as a Biomarker in Psychedelic Assisted Psychotherapy

European Psychiatry April 1, 2025 L. Cazorla, Sylvie Alaux, Cédric Mabilais et al.

Introduction One of the main mechanisms of action of LSD in psychedelic-assisted psychotherapy (PAP) is the activation of 5HT2A receptors. This triggers a cascade of neurochemical processes with the release of neurotransmitters and neurohormonal substances. The release of oxytocin in this process is well documented in pre-clinical studies, with recent evidence in healthy subjects. We have no...

Webbed Attachments: Psychedelic Lessons from the Multiverse

Theory & Event April 1, 2025 Ramzi Fawaz 1 citation

Abstract: This essay explores how the fundamental qualities of the psychedelic experience—including heightened affective intensity, the disorganization of the ego, and a sense of cosmic interconnectedness with the universe—offers a hopeful alternative to contemporary left-wing identitarianism. This is a widely popular political logic that associates the pursuit of social justice with the...

Antidepressant effect of ketamine unrelated to dissociation: Results from an exploratory mediation analysis of the KET01-02 study

European Psychiatry April 1, 2025 Lars Arvastson, Evangelos Papanastasiou, Karin Schmid et al.

IntroductionCurrent ketamine-based therapies for treatment-resistant depression (TRD) can induce dissociative symptoms. A novel oral prolonged-release ketamine formulation (KET01) results in a lower and delayed peak concentration of ketamine, and a higher concentration of the metabolites norketamine and hydroxynorketamine than after intravenous administration. KET01 has limited dissociative...

Comparing Substance Use Consequences between Serotonergic Psychedelics, MDMA, and other Drugs of Abuse Among United States Adults with History of Psychiatric Illness

International Journal of Mental Health and Addiction April 1, 2025 Joshua C. Black, Nicole Schow, Hannah L. Burkett et al. 3 citations

Psychedelic-assisted therapy could transform treating psychiatric illness, but harms from exacerbating substance use disorder (SUD) among adults with psychiatric illness using psychedelics have not been studied. A cross-sectional survey in the US was used to test whether Drug Abuse Screening Test scores (DAST-10, validated instrument predicting SUD) were more severe when psychiatric illnesses...

Tripping on Mushrooms with Edward Said: The Case for Literary Studies as Holistic Medicine

South Atlantic Quarterly April 1, 2025 Ramzi Fawaz

This piece introduces the special issue of SAQ “Psychedelic Imaginaries,” which collates fresh and theoretically sophisticated humanist perspectives on the contemporary psychedelic renaissance. Recent interdisciplinary research into psychoactive substances like LSD (or “acid”), psilocybin (or “magic mushrooms”), and MDMA (or “ecstasy”) has repeatedly shown that the therapeutically beneficial...

Reconsidering evidence for psychedelic-induced psychosis: An overview of reviews, a systematic review, and meta-analysis of human studies

European Psychiatry April 1, 2025 Michel Sabé 3 citations

Introduction Persons with schizophrenia are currently excluded from psychedelic-assisted therapy due to concerns about psychedelic-induced acute or persistent psychotic symptoms. However, meta-analytic evidence of the precise risk for psychedelic-induced de novo and exacerbation of psychosis in people with pre-existing psychotic disorders is lacking. Objectives We conducted an overview of...